BioCentury | Feb 21, 2018
Distillery Therapeutics

Cancer

...Phase Ib testing to treat recurrent or refractory metastatic pancreatic cancer. Eli Lilly also has LY2382770...
BioCentury | Aug 18, 2016
Distillery Therapeutics

Therapeutics: Transforming growth factor β 1 (TGFB1)

...testing TGFB1 inhibitors in mouse models of other metastatic cancers. Eli Lilly and Co. has LY2382770...
BioCentury | Apr 23, 2015
Distillery Therapeutics

Therapeutics: Transforming growth factor (TGF) β

...superfamily, in Phase II testing to treat anemia and thalassemia. Eli Lilly and Co. has LY2382770...
BioCentury | Jan 13, 2014
Product Development

Niche play on TGF beta

...effects. Eight companies have candidates in Phase II testing. Eli Lilly and Co. has two: LY2382770...
BioCentury | Nov 7, 2013
Distillery Therapeutics

Indication: Infectious disease

...TGFB1 immunomodulator, in Phase II testing to treat multiple sclerosis (MS). Eli Lilly and Co.'s LY2382770...
BioCentury | Mar 21, 2013
Targets & Mechanisms

Understanding fibrosis

...Phase II Digna Biotech Disitertide (P144) Dermatology Dermatology Phase II Eli Lilly and Co. (NYSE:LLY) LY2382770...
Items per page:
1 - 6 of 6